Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 14 de 14
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Neuroscience ; 183: 251-64, 2011 Jun 02.
Article de Anglais | MEDLINE | ID: mdl-21496476

RÉSUMÉ

In this study, we explored the capacity of the naturally occurring compound solasodine to promote neurogenesis in vitro and in vivo. Mouse embryonic teratocarcinoma P19 cells exposed to solasodine for 2 days followed by a 5-day washout differentiated into cholinergic neurons that expressed specific neuronal markers and displayed important axonal formation that continued growing even 30 days after treatment. In vivo, a 2-week infusion of solasodine into the left ventricle of the rat brain followed by a 3-week washout resulted in a significant increase in bromodeoxyuridine uptake by cells of the ependymal layer, subventricular zone, and cortex that co-localized with doublecortin immunostaining, demonstrating the proliferative and differentiating properties of solasodine on neuronal progenitors. In addition, these data demonstrate that under our experimental conditions adult ependymal cells retrieved their proliferative and differentiating abilities. The GAP-43/HuD pathway was activated both in vitro and in vivo, suggesting a role in the differentiating process triggered by solasodine. Solasodine treatment in rats resulted in a dramatic increase in expression of the cholesterol- and drug-binding translocator protein in ependymal cells, suggesting a possible role played by neurosteroid production in solasodine-induced neurogenesis. In GAD65-GFP mice that express the green fluorescent protein under the control of the glutamic acid decarboxylase 65-kDa promoter, solasodine treatment increased the number of GABAergic progenitors and neuroblasts generated in the subventricular zone and present in the olfactory migratory tract. Taken together, these results suggest that solasodine offers an interesting approach to stimulate in situ neurogenesis from resident neuronal progenitors as part of neuron replacement therapy.


Sujet(s)
Encéphale/cytologie , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Neurogenèse/effets des médicaments et des substances chimiques , Neurones/effets des médicaments et des substances chimiques , Alcaloïdes des Solanaceae/pharmacologie , Stéroïdes/pharmacologie , Animaux , Encéphale/effets des médicaments et des substances chimiques , Broxuridine/métabolisme , Protéines de transport/métabolisme , Différenciation cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire , Protéines à domaine doublecortine , Protéine doublecortine , Humains , Mâle , Souris , Protéines associées aux microtubules/métabolisme , Protéines de tissu nerveux/métabolisme , Neurites/effets des médicaments et des substances chimiques , Neurones/cytologie , Neuropeptides/métabolisme , Liaison aux protéines/effets des médicaments et des substances chimiques , Dosage radioimmunologique/méthodes , Rats , Rat Long-Evans , Récepteurs GABA-A/métabolisme , Tératocarcinome/anatomopathologie , Facteurs temps
2.
Neuroscience ; 165(2): 427-35, 2010 Jan 20.
Article de Anglais | MEDLINE | ID: mdl-19850110

RÉSUMÉ

Alzheimer's disease (AD), the most prominent form of dementia in elderly, is a yet incurable degenerative neurological illness characterized by memory loss. Here, we used an AD rat model to investigate the in vivo efficacy of caprospinol, a disease-modifying steroid developed on the concept that reduced synthesis of 22R-hydroxycholesterol in the AD brain increases beta-amyloid neurotoxicity. Caprospinol treatment of diseased rats attenuated memory impairment, as assessed using Morris watermaze tests. This recovery of cognitive function was accompanied by a reduction in hippocampal amyloid deposits, astrogliosis, neurodegeneration and Tau protein phopshorylation. In parallel studies, caprospinol bioavailability in normal rat forebrain was found to be dependent on the dose and duration of the treatment, demonstrating the ability of the compound to cross the blood-brain barrier. These results position caprospinol as a promising drug candidate for AD treatment.


Sujet(s)
Maladie d'Alzheimer/traitement médicamenteux , Diosgénine/analogues et dérivés , Troubles de la mémoire/traitement médicamenteux , Neuroprotecteurs/pharmacologie , Plaque amyloïde/effets des médicaments et des substances chimiques , Maladie d'Alzheimer/complications , Maladie d'Alzheimer/anatomopathologie , Animaux , Astrocytes/effets des médicaments et des substances chimiques , Astrocytes/anatomopathologie , Caproates , Troubles de la cognition/traitement médicamenteux , Troubles de la cognition/étiologie , Troubles de la cognition/anatomopathologie , Diosgénine/administration et posologie , Diosgénine/pharmacocinétique , Diosgénine/pharmacologie , Modèles animaux de maladie humaine , Gliose/traitement médicamenteux , Gliose/anatomopathologie , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Hippocampe/anatomopathologie , Mâle , Apprentissage du labyrinthe/effets des médicaments et des substances chimiques , Troubles de la mémoire/étiologie , Troubles de la mémoire/anatomopathologie , Dégénérescence nerveuse/traitement médicamenteux , Dégénérescence nerveuse/anatomopathologie , Neuroprotecteurs/administration et posologie , Neuroprotecteurs/pharmacocinétique , Phosphorylation/effets des médicaments et des substances chimiques , Plaque amyloïde/anatomopathologie , Prosencéphale/effets des médicaments et des substances chimiques , Prosencéphale/métabolisme , Prosencéphale/anatomopathologie , Rats , Rat Long-Evans , Spirostanes , Protéines tau/métabolisme
3.
Neuroscience ; 148(2): 441-53, 2007 Aug 24.
Article de Anglais | MEDLINE | ID: mdl-17689017

RÉSUMÉ

Recently, we have shown that 22R-hydroxycholesterol, a steroid intermediate in the pathway of pregnenolone formation from cholesterol, is present at lower levels in Alzheimer's disease (AD) hippocampus and frontal cortex tissue specimens than in age-matched controls, and that this substance protects against cell death induced by amyloid beta-peptide in both rat sympathetic nerve pheochromocytoma (PC12) and differentiated human Ntera2/D1 teratocarcinoma neurons. Herein we report that 22R-hydroxycholesterol inhibits the proliferation of human Ntera2/D1 teratocarcinoma precursor cells (NT2) and induces these cells to differentiate into "neuron-like" or "astrocyte-like" cells. 22R-Hydroxycholesterol-induced differentiation of NT2 cells is associated with increases in the expression of neurofilament protein NF200, the cytoskeletal proteins microtubule-associated protein type II (MAP2) a and MAP2b, glial fibrillary acidic protein (GFAP) and glial cell line-derived neurotrophic factor receptor-alpha 2 (GFRalpha2). These effects of 22R-hydroxycholesterol are considered to be stereospecific because its enantiomer 22S-hydroxycholesterol and other steroids failed to induce differentiation of NT2 cells. 22R-Hydroxycholesterol was found to lack specific binding for numerous receptors, including all steroid receptors tested. However, using a cholesterol protein binding blot assay we demonstrated the presence of a 22R-hydroxycholesterol-binding protein in NT2 cells distinct from the human oxysterol receptors liver X receptor LXRalpha and beta.


Sujet(s)
Différenciation cellulaire/effets des médicaments et des substances chimiques , Hydroxycholestérols/pharmacologie , Neurones/physiologie , Broxuridine , Mort cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cholestérol/métabolisme , Cholestérol/pharmacologie , Relation dose-effet des médicaments , Cytométrie en flux/méthodes , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Facteurs d'échange de nucléotides guanyliques/métabolisme , Humains , Hydroxycholestérols/métabolisme , L-Lactate dehydrogenase , Protéines de tissu nerveux/métabolisme , Neurones/effets des médicaments et des substances chimiques , Tératocarcinome , Sels de tétrazolium , Thiazoles , Facteurs temps , Tritium/métabolisme , Facteur ras d'échange de nucléotides guanyliques
4.
Anal Biochem ; 324(1): 123-30, 2004 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-14654054

RÉSUMÉ

A specific and sensitive methodology for the quantitative determination of hydroxysteroids dehydroepiandrosterone and pregnenolone and their main metabolites in human plasma is described. Hydroxysteroids were extracted using methanol and steroids were further separated by reverse-phase high-performance liquid chromatography, allowing for minimization of the possible chromatographic interferences. Eluted fractions were collected, pooled, and analyzed by gas chromatography-mass spectrometry as trimethylsilyl ether derivatives. The quantification was performed with single-ion monitoring of the highly abundant m/z 129 or m/z 358 fragments. The combination of the chromatographic characteristics to the specific fragments ensured the selectivity and specificity of the method. Under these conditions the method was linear (typical R2 is superior to 0.98 for all hydroxysteroids studied) over the concentration range of 2 x 10(-9) to 10(-6)M with good precision and accuracy.


Sujet(s)
Hydroxystéroïdes/sang , Biotransformation , Chromatographie en phase liquide à haute performance , Déhydroépiandrostérone/sang , Déhydroépiandrostérone/métabolisme , Chromatographie gazeuse-spectrométrie de masse/méthodes , Humains , Hydroxystéroïdes/composition chimique , Structure moléculaire , Prégnénolone/sang , Prégnénolone/métabolisme , Dosage radioimmunologique , Reproductibilité des résultats , Spectrophotométrie , Facteurs temps
5.
Gen Hosp Psychiatry ; 23(4): 183-92, 2001.
Article de Anglais | MEDLINE | ID: mdl-11543844

RÉSUMÉ

This study examined the effects of mindfulness-based stress reduction (MBSR) on health-related quality of life and physical and psychological symptomatology in a heterogeneous patient population. Patients (n=136) participated in an 8-week MBSR program and were required to practice 20 min of meditation daily. Pre- and post-intervention data were collected by using the Short-Form Health Survey (SF-36), Medical Symptom Checklist (MSCL) and Symptom Checklist-90 Revised (SCL-90-R). Health-related quality of life was enhanced as demonstrated by improvement on all indices of the SF-36, including vitality, bodily pain, role limitations caused by physical health, and social functioning (all P<.01). Alleviation of physical symptoms was revealed by a 28% reduction on the MSCL (P<.0001). Decreased psychological distress was indicated on the SCL-90-R by a 38% reduction on the Global Severity Index, a 44% reduction on the anxiety subscale, and a 34% reduction on the depression subscale (all P<.0001). One-year follow-up revealed maintenance of initial improvements on several outcome parameters. We conclude that a group mindfulness meditation training program can enhance functional status and well-being and reduce physical symptoms and psychological distress in a heterogeneous patient population and that the intervention may have long-term beneficial effects.


Sujet(s)
Comportement en matière de santé , Psychothérapie/méthodes , Qualité de vie , Stress psychologique/thérapie , Adulte , Sujet âgé , Femelle , Humains , Mâle , Méditation , Adulte d'âge moyen , Observance par le patient , Surveillance de la population , Études prospectives
6.
J Neurosci ; 21(16): 6405-12, 2001 Aug 15.
Article de Anglais | MEDLINE | ID: mdl-11487664

RÉSUMÉ

The photopigment in the human eye that transduces light for circadian and neuroendocrine regulation, is unknown. The aim of this study was to establish an action spectrum for light-induced melatonin suppression that could help elucidate the ocular photoreceptor system for regulating the human pineal gland. Subjects (37 females, 35 males, mean age of 24.5 +/- 0.3 years) were healthy and had normal color vision. Full-field, monochromatic light exposures took place between 2:00 and 3:30 A.M. while subjects' pupils were dilated. Blood samples collected before and after light exposures were quantified for melatonin. Each subject was tested with at least seven different irradiances of one wavelength with a minimum of 1 week between each nighttime exposure. Nighttime melatonin suppression tests (n = 627) were completed with wavelengths from 420 to 600 nm. The data were fit to eight univariant, sigmoidal fluence-response curves (R(2) = 0.81-0.95). The action spectrum constructed from these data fit an opsin template (R(2) = 0.91), which identifies 446-477 nm as the most potent wavelength region providing circadian input for regulating melatonin secretion. The results suggest that, in humans, a single photopigment may be primarily responsible for melatonin suppression, and its peak absorbance appears to be distinct from that of rod and cone cell photopigments for vision. The data also suggest that this new photopigment is retinaldehyde based. These findings suggest that there is a novel opsin photopigment in the human eye that mediates circadian photoreception.


Sujet(s)
Rythme circadien/physiologie , Mélatonine/sang , Cellules photoréceptrices de vertébré/classification , Adolescent , Adulte , Rythme circadien/effets des radiations , Relation dose-effet des rayonnements , Oeil/effets des médicaments et des substances chimiques , Oeil/métabolisme , Oeil/effets des radiations , Femelle , Humains , Lumière , Mâle , Mydriatiques/administration et posologie , Stimulation lumineuse/instrumentation , Stimulation lumineuse/méthodes , Cellules photoréceptrices de vertébré/métabolisme , Cellules photoréceptrices de vertébré/effets des radiations , Opsines des bâtonnets/biosynthèse , Opsines des bâtonnets/classification , Facteurs temps
7.
Psychopharmacology (Berl) ; 153(4): 402-14, 2001 Feb.
Article de Anglais | MEDLINE | ID: mdl-11243487

RÉSUMÉ

RATIONALE: St. John's wort (Hypericum perforatum) has recently gained popularity as an alternative treatment for mild to moderate depression. Given the current widespread use of this herbal remedy, it is important for medical professionals to understand the potential pharmacological pathways through which Hypericum may exert an antidepressant effect. OBJECTIVES: (1) To review the current pharmacological, toxicological, and clinical literature available on Hypericum, and (2) to provide a synthesis of this information into a form that may be easily used by health care providers. METHOD: A comprehensive review of the recent scientific literature (January 1990-March 2000) was performed using the following electronic databases and reference publications: MEDLINE, The Cochrane Library, HealthSTAR, Current Contents (all editions), European Scientific Cooperative on Phytotherapy monographs, German Commission E monographs, and the Physicians' Desk Reference for Herbal Medicines, 1st edition. RESULTS: One hundred and seven (107) publications in the English language and three publications in German were included in the review. Collectively, the data suggest that therapeutic preparations of Hypericum extract appear to exert potentially significant pharmacological activity within several neurochemical systems believed to be implicated in the pathophysiology of depression. However, little information exists regarding the safety of Hypericum, including potential herb-drug interactions. CONCLUSIONS: Additional research on the pharmacological and biochemical activity of Hypericum and its several bioactive constituents is necessary to further elucidate the mode(s) of antidepressant action. Given what is currently known and unknown about the biological properties of Hypericum, those who choose to use this herb should be closely monitored by a physician.


Sujet(s)
Hypericum/usage thérapeutique , Phytothérapie , Plantes médicinales , Animaux , Interactions médicamenteuses , Humains , Hypericum/effets indésirables , Hypericum/composition chimique , Hypericum/toxicité , Législation sur les produits chimiques ou pharmaceutiques , Extraits de plantes
8.
J Clin Endocrinol Metab ; 86(1): 433-6, 2001 Jan.
Article de Anglais | MEDLINE | ID: mdl-11232036

RÉSUMÉ

The aim of this study was to test if the three cone photopic visual system is the primary ocular photoreceptor input for human circadian regulation by determining the effects of different wavelengths on light-induced melatonin suppression. Healthy subjects with stable sleeping patterns (wake-up time 7:30 AM +/- 12 min) and normal color vision were exposed at night to full-field 505 nm or 555 nm monochromatic stimuli or darkness for 90 min. Plasma collected before and after exposures was quantified for melatonin. Subjects exposed to 10 irradiances at 505 nm showed no significant differences across mean pre-exposure melatonin values (F=0.505). A sigmoidal fluence-response curve fitted to the melatonin suppression data (R(2)=0.97) indicated that 9.34 x 10(12) photons/cm(2)/sec induced a half-saturation response (ED(50)) while 6.84 x 10(13) photons/cm(2)/sec induced a saturation melatonin suppression response. Further, a dose of 4.19 x 10(13) photon/cm(2)/sec at 505 nm was significantly stronger (P < 0.01) than an equal photon dose at 555 nm for melatonin suppression. These data demonstrate that the cone system that mediates human photopic vision is not the primary photoreceptor system to tranduce light stimuli for melatonin regulation.


Sujet(s)
Lumière , Mélatonine/métabolisme , Cellules photoréceptrices en cône de la rétine/physiologie , Voies optiques/physiologie , Adulte , Femelle , Humains , Mâle , Stimulation lumineuse , Photons
9.
Int J Psychiatry Med ; 30(3): 203-19, 2000.
Article de Anglais | MEDLINE | ID: mdl-11209989

RÉSUMÉ

OBJECTIVE: The objective of this article is to review the current knowledge of the pharmacology, sites of action, and therapeutic effectiveness of St. John's Wort. METHOD: The method used was a review of the available literature, using keywords to search the medline database. Bibliographies of the papers, thus obtained, were searched for further documents not referenced by medline. We reviewed papers from this collection. RESULTS: This review reveals that most of the available data on efficacy and safety of St. John's Wort involve its use in mild to moderate depression. Much, but not all of the prevailing opinion is positive. Nevertheless, the quality of therapeutic trials vary so greatly that definitive conclusions are not possible. Both the source and mode of St. John's Wort's therapeutic effect are unclear. We need further controlled studies of effectiveness, safety, and mode of action. In addition to its use in depression, there are reports suggesting possible therapeutic effects in other conditions such as certain malignancies and infections, but these are far too preliminary to permit any conclusions.


Sujet(s)
Antidépresseurs/usage thérapeutique , Dépression/traitement médicamenteux , Hypericum/usage thérapeutique , Phytothérapie , Plantes médicinales , Antidépresseurs/métabolisme , Essais cliniques comme sujet , Thérapies complémentaires , Humains , Hypericum/métabolisme , Résultat thérapeutique
11.
Percept Mot Skills ; 88(3 Pt 1): 1019-28, 1999 Jun.
Article de Anglais | MEDLINE | ID: mdl-10407911

RÉSUMÉ

This study investigated differences in values of manual muscle tests after exposure to congruent and incongruent semantic stimuli. Muscle testing with a computerized dynamometer was performed on the deltoid muscle group of 89 healthy college students after repetitions of congruent (true) and incongruent (false) self-referential statements. The order in which statements were repeated was controlled by a counterbalanced design. The combined data showed that approximately 17% more total force over a 59% longer period of time could be endured when subjects repeated semantically congruent statements (p < .001). Order effects were not significant. Over-all, significant differences were found in muscle-test responses between congruent and incongruent semantic stimuli.


Sujet(s)
Bras/physiologie , Ergométrie/statistiques et données numériques , Muscles squelettiques/physiologie , Concept du soi , Comportement verbal/physiologie , Adolescent , Adulte , Phénomènes biomécaniques , Femelle , Latéralité fonctionnelle/physiologie , Humains , Cinésiologie appliquée , Mâle , Contraction musculaire/physiologie , Effort physique/physiologie , Sémantique , Articulation glénohumérale/physiologie
12.
J Am Acad Dermatol ; 13(6): 999-1003, 1985 Dec.
Article de Anglais | MEDLINE | ID: mdl-3935693

RÉSUMÉ

Two patients with multiple cutaneous neurofibromas restricted to a dermatomal portion of the skin are described. Neither patient had clinical evidence or a family history of generalized neurofibromatosis. Whether this represents a distinct disorder, sui generis, or a variant in the spectrum of neurofibromatosis is unknown.


Sujet(s)
Neurofibromatose de type 1/anatomopathologie , Tumeurs cutanées/anatomopathologie , Peau/anatomopathologie , Adolescent , Femelle , Humains , Mâle , Adulte d'âge moyen , Neurofibromatose de type 1/génétique , Tumeurs cutanées/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE